Viridian Therapeutics, Inc. (VRDN)

Viridian Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	776	1,145	1,176	429	64	15
Market Cap Growth	0.71%	-2.58%	173.76%	567.53%	321.72%	-83.67%
Enterprise Value	183	688	756	232	-63	-3
PE Ratio	-	-4.82	-9.05	-5.41	-0.58	-0.36
PS Ratio	2694.73	3647.53	663.46	144.94	61.27	3.42
PB Ratio	1.33	2.59	2.98	2.29	0.54	0.97
P/FCF Ratio	-6.53	-6.19	-12.42	-7.83	-2.16	-0.42
P/OCF Ratio	-6.56	-6.22	-12.53	-7.87	-2.16	-0.42
EV/Sales Ratio	636.19	2191.59	426.49	78.46	-60.29	-0.74
EV/EBITDA Ratio	-2.35	-2.92	-5.85	-2.93	0.58	0.08
EV/EBIT Ratio	-2.35	-2.92	-5.84	-2.93	0.57	0.08
EV/FCF Ratio	-3.01	-3.72	-7.99	-4.24	2.12	0.09
Debt / Equity Ratio	0.03	0.05	0.01	-	-	0.53
Debt / EBITDA Ratio	-0.09	-0.09	-0.04	-	-	-0.20
Debt / FCF Ratio	-0.12	-0.11	-0.05	-	-	-0.23
Quick Ratio	23.47	17.93	12.73	14.48	11.96	2.64
Current Ratio	23.99	18.27	12.93	14.68	12.14	2.92
Asset Turnover	0.00	0.00	0.01	0.02	0.02	0.10
Interest Coverage	-95.13	-127.71	-266.23	-26470.00	-216.94	-49.15
Return on Equity (ROE)	-53.70%	-68.30%	-46.70%	-53.20%	-234.00%	-147.80%
Return on Assets (ROA)	-48.40%	-61.10%	-42.30%	-47.70%	-187.20%	-96.90%
Return on Capital (ROIC)	-39.46%	-55.05%	-33.60%	-42.47%	-91.95%	-174.49%
Earnings Yield	-28.11%	-20.76%	-11.05%	-18.49%	-172.09%	-274.48%
FCF Yield	-21.67%	-16.16%	-8.05%	-12.77%	-46.35%	-236.90%
Buyback Yield / Dilution	-44.64%	-39.48%	-169.22%	-235.07%	-70.27%	-5.87%
Total Shareholder Return	-44.64%	-39.48%	-169.22%	-235.07%	-70.27%	-5.87%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).